Evaluation of Pharmacokinetic Interactions Between the New SGLT2 Inhibitor SHR3824 and Valsartan in Healthy Chinese Volunteers



      Hypertension is often observed in patients with diabetes, and the progression of diabetic nephropathy is closely related to blood pressure elevation. Thus, the effects of hypoglycemic drugs on kidney function and pharmacokinetic interactions in combination with antihypertensive and hypoglycemic drugs are of great clinical value. The purpose of this study was to evaluate the pharmacokinetic interactions between henagliflozin (SHR3824), a new sodium-dependent glucose transporter 2 (SGLT2) inhibitor class drug, and valsartan, an angiotensin II receptor blocker.


      A single-center, single-arm, open-label, self-controlled study was conducted in healthy Chinese volunteers. The pharmacokinetic parameters were calculated with Phoenix WinNonlin version 7.0, and the statistical analysis was performed with SAS version 9.4. Data on pharmacokinetic parameters (single and/or steady-state) were collected and tabulated for different analytes (valsartan and SHR3824) according to the sampling time specified in the protocol. Continuous attention was paid to the safety of all subjects. The aim of the study was to evaluate the effect of a single dose of valsartan on the pharmacokinetic behavior of SHR3824 after multiple doses of SHR3824 (Cmax,ss and AUCτ,ss) and the effect of multiple doses of SHR3824 on the pharmacokinetic behavior of valsartan (Cmax, AUC0–24h, and AUC0–∞). A mixed effect model was used to estimate the point estimation and 90% CI of the geometric mean ratio of the corresponding pharmacokinetic indices at the combined-medication stage (SHR3824 + valsartan) and the single-medication stage (SHR3824 or valsartan).


      Twelve volunteers were screened into this experiment and underwent blood sampling. The pharmacokinetic properties of SHR3824 were evaluated after its administration alone or in combination with valsartan. Point estimates and 90% CIs of the geometric mean ratio of SHR3824 Cmax,ss and AUCτ,ss were within the conventional bioequivalence range of 80% to 125%. The pharmacokinetic properties of valsartan were evaluated after its administration alone or in combination with SHR3824. The geometric mean ratios and 90% CIs of the valsartan Cmax, AUC0–24h, and AUC0–∞ were also within the range of 80% to 125%. Thirty-four mild adverse events were reported, with no serious adverse events or suspected unexpected serious adverse reactions.


      This study provides basis for the clinical co-administration of SHR3824 with angiotensin II receptor blockers represented by valsartan. Based on these findings, co-administration of SHR3824 and valsartan seemed to have no effect on the pharmacokinetic properties of either drug. Identifier: CTR20180002.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ferrannini E
        • Cushman WC.
        Diabetes and hypertension: the bad companions.
        Lancet Lond Engl. 2012; 380: 601-610
        • Strain WD
        • Paldánius PM.
        Correction to: diabetes, cardiovascular disease and the microcirculation.
        Cardiovasc Diabetol. 2021; 20: 120
        • Krzesinski JM
        • Weekers L.
        [Hypertension and diabetes].
        Rev Med Liege. 2005; 60: 572-577
        • Oparil S
        • Acelajado MC
        • Bakris GL
        • et al.
        Nat Rev Dis Primer. 2018; 4: 18014
        • Oshima M
        • Shimizu M
        • Yamanouchi M
        • et al.
        Trajectories of kidney function in diabetes: a clinicopathological update.
        Nat Rev Nephrol. 2021; 17: 740-750
        • Lonati C
        • Morganti A
        • Comarella L
        • Mancia G
        • Zanchetti A
        • Study Group IPERDIA
        Prevalence of type 2 diabetes among patients with hypertension under the care of 30 Italian clinics of hypertension: results of the (Iper)tensione and (dia)bete study.
        J Hypertens. 2008; 26: 1801-1808
        • Scheen AJ.
        Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
        Drugs. 2015; 75: 33-59
        • Jaikumkao K
        • Pongchaidecha A
        • Chatsudthipong V
        • Chattipakorn SC
        • Chattipakorn N
        • Lungkaphin A.
        The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
        Biomed Pharmacother Biomedecine Pharmacother. 2017; 94: 176-187
        • Sridhar VS
        • Rahman HU
        • Cherney DZI.
        What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?.
        Diabetes Obes Metab. 2020; 22 (Suppl): 55-68
        • Abdel-Wahab AF
        • Bamagous GA
        • Al-Harizy RM
        • et al.
        Renal protective effect of SGLT2 inhibitor dapagliflozin alone and in combination with irbesartan in a rat model of diabetic nephropathy.
        Biomed Pharmacother Biomedecine Pharmacother. 2018; 103: 59-66
        • Chen Z
        • Li L
        • Zhan Y
        • et al.
        Characterization and quantitative determination of henagliflozin metabolites in humans.
        J Pharm Biomed Anal. 2021; 192113632
        • Weng J
        • Zeng L
        • Zhang Y
        • et al.
        Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
        Diabetes Obes Metab. 2021; 23: 1754-1764
        • Zhang YF
        • Liu YM
        • Yu C
        • et al.
        Tolerability, pharmacokinetic, and pharmacodynamic profiles of henagliflozin, a novel selective inhibitor of sodium-glucose cotransporter 2, in healthy subjects following single- and multiple-dose administration.
        Clin Ther. 2021; 43: 396-409
        • Vasilakou D
        • Karagiannis T
        • Athanasiadou E
        • et al.
        Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.
        Ann Intern Med. 2013; 159: 262-274
        • Black HR
        • Graff A
        • Shute D
        • et al.
        Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
        J Hum Hypertens. 1997; 11: 483-489
        • Black HR
        • Bailey J
        • Zappe D
        • Samuel R.
        Valsartan: more than a decade of experience.
        Drugs. 2009; 69: 2393-2414
        • Durmus S
        • Lozano-Mena G
        • van Esch A
        • Wagenaar E
        • van Tellingen O
        • Schinkel AH.
        Preclinical mouse models to study human OATP1B1- and OATP1B3-mediated drug-drug interactions in vivo.
        Mol Pharm. 2015; 12: 4259-4269
        • Ripley TL.
        Valsartan in chronic heart failure.
        Ann Pharmacother. 2005; 39: 460-469
        • Maeda K
        • Ieiri I
        • Yasuda K
        • et al.
        Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
        Clin Pharmacol Ther. 2006; 79: 427-439
      1. Beijing Novartis Pharma Ltd. Instructions of Valsartan Capsules (Trade name: Daiwen).

        • Ayalasomayajula S
        • Han Y
        • Langenickel T
        • et al.
        In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696).
        J Clin Pharm Ther. 2016; 41: 424-431
        • Mamidi RNVS
        • Dallas S
        • Sensenhauser C
        • et al.
        In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
        Br J Clin Pharmacol. 2017; 83: 1082-1096
        • Hanna I
        • Alexander N
        • Crouthamel MH
        • et al.
        Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
        Xenobiotica. 2018; 48: 300-313
        • Wang L
        • Wu C
        • Shen L
        • et al.
        Evaluation of drug-drug interaction between henagliflozin, a novel sodium-glucose co-transporter 2 inhibitor, and metformin in healthy Chinese males.
        Xenobiotica Fate Foreign Compd Biol Syst. 2016; 46: 703-708
        • Jangala H
        • Vats P
        • Khuroo AH
        • Monif T.
        Development and validation of a LC-MS/MS method for the simultaneous estimation of amlodipine and valsartan in human plasma: application to a bioequivalence study.
        Sci Pharm. 2014; 82: 585-600
      2. Center For Drug Evaluation. Technical Guidelines for Drug Interaction Studies (Draft). Accessed February 27, 2022.

        • Lee J
        • Lee H
        • Jang K
        • Lim KS
        • Shin D
        • Yu KS.
        Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers.
        Drug Des Devel Ther. 2014; 8: 1781-1788
        • Seong SJ
        • Ohk B
        • Kang WY
        • et al.
        Pharmacokinetic drug interactions between amlodipine, valsartan, and rosuvastatin in healthy volunteers.
        Adv Ther. 2019; 36: 1642-1656
        • Hedaya MA
        • Helmy SA.
        Pharmacokinetic interactions of valsartan and hydrochlorothiazide: an open-label, randomized, 4-period crossover study in healthy Egyptian male volunteers.
        Clin Ther. 2013; 35: 846-861
        • Kasichayanula S
        • Chang M
        • Liu X
        • et al.
        Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin.
        Adv Ther. 2012; 29: 163-177
        • Yong X
        • Wen A
        • Liu X
        • et al.
        Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus.
        Clin Drug Investig. 2016; 36: 195-202
        • Jung JA
        • Lee SY
        • Kim JR
        • et al.
        A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
        Drug Des Devel Ther. 2015; 9: 745-752
        • Feng B
        • Wang P
        • Ning Z.
        Literature analysis of 74 cases of adverse reactions caused by valsartan.
        Chin J New Drugs. 2010; 19 ([in Chinese]): 1094-1096
        • Qiu H
        • Novikov A
        • Vallon V.
        Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives.
        Diabetes Metab Res Rev. 2017; : 33
        • Lu J
        • Fu L
        • Li Y
        • et al.
        Henagliflozin monotherapy in patients with type 2 diabetes inadequately controlled on diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
        Diabetes Obes Metab. 2021; 23: 1111-1120